A vaccine awaiting Corona in September

Nasr Al-Majali: London has revealed that a coronavirus vaccine could be ready by September, and Sarah University Oxford professor Sarah Sarah Gilbert, who is currently leading Britain’s most advanced research on a vaccine, said it is “80 percent safe” that your team development will work in the fall.

Gilbert said he expected the vaccine to be developed by the end of 2020, but has now confirmed the more optimistic scenario after human trials begin in the next two weeks.

And British reports, in late March and reported by Elaf, said that human and animal experiments with a British Corona virus vaccine will begin in a few weeks at the government’s secret science base (Burton Down) in the county. from Wiltshire.

Scientists will test the drug, made at the University of Oxford, on animals in the base before testing it on humans this week. Oxford scientists hope that the vaccine, which contains a section of the coronavirus genetic code, will enable the body to attack the virus.

Animal experiments

The second-phase trials will begin before the results of the animal experiments are known, the newspaper said, as the crisis moves to its next dramatic stage, however, experts warned that the Covid vaccine- 19 is not imminent.

The British government had previously announced that it would finance the manufacturing of millions of vaccine doses that looked promising in advance, allowing for immediate availability to the public once it was developed.

Furthermore, despite previous warnings that vaccine production could take up to 18 months, Professor Gilbert said the most optimistic scenario for a product that works is September “if everything goes perfectly.”

She told the Times: “I think there is a great opportunity to work based on other things that we have done with this type of vaccine.” He added: “It is not just intuition, and with each week that passes we have more data to see. I am going to get 80 percent of Results, this is my personal point of view.”

Shutdown and test

Vaccine scientist Gilbert explained that Britain’s closure makes testing a vaccine difficult because of the virus’s inability to spread, saying: “No one can promise it will work.”
Professor Gilbert’s team was already in talks with the government about production to avoid delays and avoid a second high infection in the fall. “We don’t want to go further this year and find out that we have a highly effective vaccine and that we don’t have any vaccines to use,” he said.

Professor Sarah Gilbert, leader of the completion team.

British ministers had hinted that it could be beneficial to spend tens of millions on an effective vaccine to offset the economic cost of the shutdown. The UK is a leader in vaccine financing and last month injected £ 210m into an international fund, the largest contribution at the time to the vaccine.

Millions of doses

The government also said it would be willing to buy millions of doses if the trials were successful. However, despite Oxford’s optimism, other vaccine developers have said it may take up to a year before something is ready for distribution.

Ministers have been pressured to explain the government’s exit strategy as of its continued closure, but scientists say it is too early to consider removing large-scale restrictions as the death toll continues to rise.

Professor Robin Shattuck of Imperial College London made it clear in late March that the vaccines would not be widely available until next year “as soon as possible,” adding in a statement to (BBC): “The first part of the test is to verify it is safe in humans in small amounts and again stimulates the correct type of immune response. “

Time frame

Shattuck noted that this will take time, even if we do things quickly, over a period of two to three months, and continued: “The next stage will be to step it up and start looking at whether the vaccine can really prevent infection in society.”

“You must produce the data to show that the vaccine worked and how successful it was before you could get a license to sell it as a product,” said Professor Imperial College.

Third stage experiences

He noted that generally, third-stage trials are larger before clinical approval of the drug, “However, in emergencies, these pilot vaccines are issued early for key workers.”

Adrian Hill, director of the Jenner Institute at Oxford University, told The Guardian: “The more vaccines we can provide the sooner the better.”

Professor Hill added: We are aware that a vaccine is required as soon as possible, and certainly for June and July, when we expect a high mortality spike.

He said: “This is not a normal case, we will follow all the requirements of standard experimental safety, but once we have a vaccine that works, we hope there will be a quick way to spread to save lives, the more we can provide a vaccine the more faster, better. “

The role of chimpanzees

The Jenner Institute team had announced that it had begun work to search for a vaccine on January 10 of this year, and the institute said it had based the drug on an “adenovirus vaccine carrier” which is an adenovirus isolated from chimpanzees.

The Jenner Institute added: “Adenovirus chimpanzees are a well-studied type of vaccine that has been used safely in thousands of subjects in vaccines targeting more than 10 different diseases,” adding that its advantages include that it can ” generate a strong immune response with a single dose. ” Safe to use in people with previous conditions like diabetes. “

Topics that may interest you: